Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension

Math 1 Math(A1).

Figure 1 A: Study of laser induced thrombosis parameters; Number of shots (expressed in number): ^aP < 0. 05 vs ShP (Placebo); B: Study of laser induced thrombosis parameters; Number of Emboli (expressed in number): ^aP < 0.05 vs ShP (placebo); ^bP < 0.01 vs PHP (placebo); ^cP < 0.05 vs ShP (SC-560); C: Study of laser induced thrombosis parameters; Duration of Embolisation (expressed in minutes): ^aP < 0.05 vs ShP (placebo); ^bP < 0.001 vs PHP (placebo); D: Study of Induced Hemorrhagic Time (expressed in seconds): ^bP < 0.01 vs ShP (placebo); ^dP < 0.001 vs PHP (placebo); ^fP < 0.01 vs PHP (SC-560); ^hP < 0.001 vs PHP (placebo).

Figure 2 A: Study of Platelet aggregation induced by ADP, Amplitude (expressed in Ohm): ^aP < 0. 05 vs PHP (SC-560); ^cP < 0.05 vs PHPAs (placebo); B: Study of Platelet aggregation induced by ADP, Velocity (expressed in Ohm/min): ^aP < 0.05 vs ShP (placebo); ^bP < 0.01 vs ShP (placebo).

Figure 3 A: Plasmatic 6-keto PGF_1α concentrations (expressed in ng/mL): ^bP < 0. 01 vs ShP (placebo); ^aP < 0.05 vs PHP (placebo); ^cP < 0.05 vs PHP (placebo); B: Plasmatic TXB₂ concentrations (expressed in ng/mL): ^bP < 0.001 vs PHP (placebo); ^aP < 0.05 vs ShP (NS-398) and P < 0.001 vs PHAs (placebo); C: Plasmatic PGE₂ concentrations (expressed in ng/mL): ^aP < 0.05 vs PHP (placebo); D: Plasmatic LTB₄ concentrations (expressed in ng/mL).